started · updated
Chong Kun Dang presents preclinical results for CKD-DAC anticancer candidate
Chong Kun Dang presented preclinical research results for its next-generation anticancer drug candidate, CKD-DAC, at the 17th World ADC San Diego conference. CKD-DAC is a Degrader-Antibody Conjugate (DAC) that combines a self-developed cyclin K (CCNK) molecular glue degrader with a target antibody.
Unlike traditional Antibody-Drug Conjugates (ADCs) that use cytotoxic drugs to attack cancer cells directly, DACs use a payload to degrade specific proteins essential for cancer cell survival. In preclinical studies, the CKD-DAC payload maintained efficacy even in cell lines resistant to trastuzumab deruxtecan. It also demonstrated synergistic effects when used in combination with the PARP inhibitor olaparib.
In animal models, CKD-DAC showed tumor suppression levels comparable to trastuzumab deruxtecan. Notably, in toxicity tests conducted on rats, the CKD-DAC group showed no hematological toxicity, whereas the trastuzumab deruxtecan group exhibited such toxicity. The company plans to expand its DAC platform to develop various differentiated anticancer drugs.